Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of RLD2202 and RLD2203 (Aspirin and Rabeprazole) in Healthy Adults
NCT05481307Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aspirin and rabeprazole in cardiovascular diseases (CVD) and gastric ulcer, sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State, Area Under the Curve at Steady State over Dosing Interval and 2 more. Started Aug 2022; status: completed.
02
Drugs
aspirinrabeprazole
03
Conditions
cardiovascular diseases (CVD)gastric ulcer
Beyond the preview
Go deeper on NCT05481307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481307.